TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · major macro event coming up
INCY

Incyte Corporation

Healthcare · Biotechnology

121.60$ +0.8% vs. previous close Closing price · As of: Aug 10, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Incyte Corporation (INCY). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — INCY
Segment 2022 2023 2024 2025
Reportable Segment $3.39B 100.0% $3.70B 100.0% · +8.9% $4.24B 100.0% · +14.8% $5.14B 100.0% · +21.2%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by region

Revenue by region — INCY
Segment 2020 2021 2022 2023 2024 2025
United States $2.60B 96.1% $2.90B 95.9% · +11.5% $3.20B 95.6% · +10.3% $3.51B 95.1% · +9.8% $3.97B 93.7% · +13.1% $4.80B 93.4% · +20.8%
Europe $105.0M 3.9% $124.1M 4.1% · +18.2% $147.0M 4.4% · +18.5% $175.9M 4.8% · +19.6% $260.4M 6.1% · +48.1% $323.7M 6.3% · +24.3%
Other countries $4.9M 0.1% $6.2M 0.1% · +26.5% $17.6M 0.3% · +182.7%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 10, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?